Health Catalyst, Inc.
No SEC Form 4 filings for $HCAT in the last 30 days.
Health Catalyst (NASDAQ: HCAT) shares fell 23.1% after the company issued a weak Q3 revenue forecast and cut its full-year outlook. It expects Q3 revenue of $55.5 million versus $70.49 million in Q2, and reduced 2026 revenue guidance to $247.5 million at the midpoint. Q2 revenue met expectations, but the outlook pressured the stock.
Health Catalyst, Inc. said it closed the July 31, 2026 sale of Vitalware, LLC to Med-Metrix, LLC. The divestiture generated $147M in total cash consideration, subject to adjustments. Health Catalyst plans to use proceeds and cash on hand to fully repay its credit facility, removing about $19M in annual GAAP interest expense, and to focus on its core healthcare intelligence and AI platform.
Health Catalyst (NASDAQ:HCAT) reported Q2 CY2026 revenue of $70.49 million, down 12.7% year on year, but above analysts’ estimates by 2.1%. Non-GAAP EPS was $0.04, in line with consensus. Next-quarter revenue guidance was $55.5 million, 10.7% below estimates. The stock fell 25.5% to $1.71 after results.
Over the past 7 days, alphai's AI scored 5 news stories mentioning HCAT (Health Catalyst, Inc.). Coverage has skewed bearish: 1 bullish, 2 neutral, and 2 bearish.
Recent HCAT coverage spans earnings, corporate actions and financial news.
The guidance reset signals deteriorating demand and likely extends margin and growth pressure, driving a sharp repricing versus the prior outlook.
The deal is a balance-sheet and strategy reset: divest a non-core mid-revenue cycle unit, eliminate interest drag, and redirect capital toward its core healthcare intelligence and AI roadmap.
The print is a mixed earnings outcome: upside on Q2 revenue, but a weaker-than-expected revenue guide and ongoing YoY sales declines likely drive near-term downside risk.
The filing combines Q2 performance with a notably low Q3 Adjusted EBITDA outlook, plus balance-sheet improvement from the Vitalware divestiture and credit facility repayment.
Earnings-day positioning hinges on whether HCAT can beat the expected YoY revenue decline and whether guidance lands above the Street.
alphai scores every news story that mentions HCAT with an AI model for sentiment and relevance, and aggregates insider trades from Health Catalyst, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Health Catalyst (NASDAQ: HCAT) shares fell 23.1% after the company issued a weak Q3 revenue forecast and cut its full-year outlook. It expects Q3 revenue of $55.5 million versus $70.49 million in Q2, and reduced 2026 revenue guidance to $247.5 million at the midpoint. Q2 revenue met expectations, but the outlook pressured the stock.
4 min readHealth Catalyst, Inc. said it closed the July 31, 2026 sale of Vitalware, LLC to Med-Metrix, LLC. The divestiture generated $147M in total cash consideration, subject to adjustments. Health Catalyst plans to use proceeds and cash on hand to fully repay its credit facility, removing about $19M in annual GAAP interest expense, and to focus on its core healthcare intelligence and AI platform.
4 min readHealth Catalyst (NASDAQ:HCAT) reported Q2 CY2026 revenue of $70.49 million, down 12.7% year on year, but above analysts’ estimates by 2.1%. Non-GAAP EPS was $0.04, in line with consensus. Next-quarter revenue guidance was $55.5 million, 10.7% below estimates. The stock fell 25.5% to $1.71 after results.
6 min readHealth Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q2ex991-earningspress.htm EX-99.1 Document Exhibit 99.1 Health Catalyst Reports Second Quarter 2026 Results SALT LAKE CITY, UT, August 6, 2026 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measur
6 min readHealth Catalyst (NASDAQ: HCAT) is set to report Q2 earnings Thursday after the bell. Last quarter, it reported revenue of $70.76M, down 10.9% YoY, and missed next-quarter guidance versus analysts. Consensus expects Q2 revenue to fall 14.6% YoY. HCAT stock is near $2.28 with an average analyst price target of $2.31.
3 min readHealth Catalyst (NASDAQ:HCAT) shareholders approved the board’s director slate and an advisory vote on named executive officer compensation, and ratified the auditor appointment, according to the company. A proposal to declassify the board and elect directors annually starting in 2029 failed, falling short of a 66.67% threshold. Voting results will be filed with the SEC.
3 min readHealth Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. hcat-20260716 FALSE 0001636422 0001636422 2026-07-16 2026-07-16 0001636422 dei:FormerAddressMember 2026-07-16 2026-07-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________ FORM 8-K ____________________
2 min readGuggenheim analyst John DiFucci upgraded Salesforce and ServiceNow to Buy on valuation, arguing near-term AI monetization is unlikely and AI risks are real. The read-through lifted related stocks: Health Catalyst (+6.4%), PubMatic (+5.1%), and PTC (+6.4%). PTC recently reported Q1 2026 revenue of $774.3M and adj. EPS $2.69, beating estimates.
6 min readAn analysis from May 2026 identifies Health Catalyst (HCAT), Enphase Energy (ENPH), and World Kinect (WKC) as three stocks that have recently shown significant price gains but are underpinned by weak fundamental financial metrics. Health Catalyst struggles with plateaued billings and high marketing costs, Enphase Energy faces declining sales and free cash flow, and World Kinect operates with low gross margins and limited free cash flow. Despite their recent stock performance, the report suggests these companies may not be sustainable long-term investments due to underlying operational and financial challenges.
5 min readHealth Catalyst (HCAT) shares rose 9.4% after the company reported first-quarter 2026 results that exceeded analyst expectations for both revenue and earnings. Despite a year-over-year revenue decrease, the market reacted positively to the company surpassing current forecasts. Health Catalyst also provided guidance for the second quarter and full year 2026, with the positive investor sentiment potentially due to a broader upswing in the software-as-a-service sector.
3 min read
